Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**QS-7** is a natural saponin compound isolated from the bark of the Quillaja saponaria (QS) Molina tree, serving as a vaccine adjuvant with immunostimulating properties for anti-tumor and anti-infectious activities. It induces a balanced Th1/Th2 immune response, including strong CD8+ cytotoxic T lymphocyte (CTL) production, comparable to QS-21 but with reduced hemolytic and lethal toxicity due to its more hydrophilic structure featuring extra monosaccharide units in the C28 oligosaccharide domain and an acetyl group instead of a long chiral acyl chain at the fucosyl unit. QS-7 has molecular weight 1863.89 and formula C83H130O46, and synthetic analogs have been developed to tune its adjuvanticity, with one analog potentiating mixed Th1/Th2 responses effectively in preclinical immunization studies against antigens like rHagB and DnaK.[1][3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QS-7.